Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glucomoringin isothiocyanate
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Glucomoringin isothiocyanate (GMG-ITC), also known as moringin, is a bioactive secondary metabolite derived from the seeds of *Moringa oleifera*. It is produced through the enzymatic hydrolysis of the glucosinolate glucomoringin by the enzyme myrosinase. GMG-ITC has demonstrated significant anti-proliferative and pro-apoptotic activity in various cancer models, particularly prostate cancer (PC-3 cells). Its mechanism of action involves the induction of G2/M phase cell cycle arrest and the activation of apoptotic pathways, including the upregulation of p53, Bax, JNK, and Bad, and the activation of caspases, while modulating the Akt/MAPK signaling pathway. Research suggests its potential as a future cytotoxic agent for cancer chemotherapy.
- Other names
- moringin4-(alpha-L-rhamnopyranosyloxy)benzyl isothiocyanate
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)BAX (Apoptosis regulator BAX)CASP3 (Caspase-3)CASP8 (Caspase-8)CASP9 (Caspase-9)JNK (Mitogen-activated protein kinase kinase kinase family)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)BAD (Bcl-2-associated agonist of cell death)CASP (Caspase family)MAPK3 (Mitogen-activated protein kinase 1)TP53 (Cellular Tumor Antigen p53 R175H)
Beyond the preview
Go deeper on glucomoringin isothiocyanate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glucomoringin isothiocyanate.